MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Harrow Health Net Income 2011-2025 | HROW
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Harrow Health
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.4 M | -14.1 M | -18 M | -3.36 M | 168 K | 14.6 M | -12 M | -19.1 M | -15.9 M | -10.1 M | -7.64 M | -5.38 M | -954 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.6 M | -24.4 M | -8.93 M |
Quarterly Net Income Harrow Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.02 M | 5 M | -17.8 M | - | -4.22 M | -6.47 M | -13.6 M | - | -4.39 M | -4.23 M | -6.64 M | - | -6.46 M | -6.24 M | -2.44 M | - | -8.33 M | -2.48 M | 217 K | - | 8.64 M | -237 K | -12.9 M | - | -11.5 M | -2.38 M | 11.4 M | - | -2.51 M | 2.52 M | -3.51 M | - | -5.69 M | 1.48 M | -5.01 M | - | -3.85 M | -4.64 M | -4.5 M | - | -3.95 M | -3.73 M | -3.09 M | - | -2.45 M | -2.6 M | -2.32 M | - | -2.08 M | -2.22 M | -1.47 M | - | -1.25 M | -1.31 M | -1.38 M | - | -85.4 K | -164 K | -432 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.4 M | -17.8 M | -3.07 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-332 M | $ 0.75 | -2.02 % | $ 53.3 M | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 3.09 | -5.64 % | $ 1.66 B |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.66 | -4.48 % | $ 179 M | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-13 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-695 M | $ 5.22 | -3.33 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 11.91 | 4.29 % | $ 610 M | USA |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 4.91 | 1.76 % | $ 647 M | USA |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 26.42 | 0.49 % | $ 1.22 B | USA |
 |
Evoke Pharma
EVOK
|
-7.79 M | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | $ 21.45 | 0.4 % | $ 2.04 B |  France |
 |
Rockwell Medical
RMTI
|
-8.44 M | $ 0.9 | -2.78 % | $ 21 M | USA |
 |
Evolus
EOLS
|
-50.4 M | $ 7.2 | 2.2 % | $ 447 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
China Pharma Holdings
CPHI
|
-4.74 M | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
-592 M | $ 6.79 | -1.95 % | $ 2.48 B | Canada |
 |
Veru
VERU
|
-37.8 M | $ 2.39 | -1.15 % | $ 322 M | USA |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.85 | -3.91 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 2.96 | 17.0 % | $ 41.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
13.7 M | - | - | $ 193 M | Canada |
 |
Solid Biosciences
SLDB
|
-125 M | $ 5.79 | -1.36 % | $ 236 M | USA |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-98.8 M | $ 4.05 | -0.25 % | $ 122 M | USA |
 |
Jupiter Wellness
JUPW
|
-49.4 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-172 M | $ 12.99 | -1.14 % | $ 1.78 B | USA |
 |
ProPhase Labs
PRPH
|
18.5 M | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
-153 K | $ 1.59 | 30.33 % | $ 6.86 M | USA |
 |
Sundial Growers
SNDL
|
-230 M | $ 2.09 | -5.49 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
67 M | $ 0.64 | -1.49 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 11.19 | -7.9 % | $ 6.92 B | Canada |
 |
TherapeuticsMD
TXMD
|
-10.3 M | $ 1.74 | -0.86 % | $ 18.2 M | USA |
 |
Zomedica Corp.
ZOM
|
-34.5 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
2.08 B | $ 11.71 | 0.47 % | $ 14.2 B | USA |